Geodon: Effective Management of Schizophrenia and Bipolar Disorder
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.32 | $46.44 (0%) | 🛒 Add to cart |
| 30 | $1.63 | $69.66 $49.02 (30%) | 🛒 Add to cart |
| 60 | $1.22 | $139.32 $73.10 (48%) | 🛒 Add to cart |
| 90 | $1.02 | $208.98 $92.02 (56%) | 🛒 Add to cart |
| 120 | $0.82 | $278.64 $98.04 (65%) | 🛒 Add to cart |
| 180 | $0.74 | $417.96 $132.44 (68%) | 🛒 Add to cart |
| 270 | $0.69 | $626.94 $185.76 (70%) | 🛒 Add to cart |
| 360 | $0.65
Best per pill | $835.92 $235.64 (72%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $3.96 | $39.56 (0%) | 🛒 Add to cart |
| 20 | $2.71 | $79.12 $54.18 (32%) | 🛒 Add to cart |
| 30 | $1.89 | $118.68 $56.76 (52%) | 🛒 Add to cart |
| 60 | $1.36 | $237.36 $81.70 (66%) | 🛒 Add to cart |
| 90 | $1.18 | $356.04 $105.78 (70%) | 🛒 Add to cart |
| 120 | $1.09 | $474.72 $130.72 (72%) | 🛒 Add to cart |
| 180 | $1.04 | $712.08 $187.48 (74%) | 🛒 Add to cart |
| 270 | $1.02 | $1068.12 $274.34 (74%) | 🛒 Add to cart |
| 360 | $1.00
Best per pill | $1424.16 $359.48 (75%) | 🛒 Add to cart |
Geodon (ziprasidone) is an atypical antipsychotic medication designed to provide robust symptom control in adults with schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. It functions by modulating dopamine and serotonin activity in the brain, targeting the core neurochemical imbalances implicated in these conditions. Available in both oral capsule and intramuscular injection formulations, it offers flexibility in treatment settings, from long-term outpatient management to rapid intervention in acute psychiatric crises. Its distinct receptor binding profile contributes to its efficacy while potentially mitigating certain metabolic side effects associated with older antipsychotics.
Features
- Active ingredient: ziprasidone hydrochloride
- Available formulations: oral capsules (20 mg, 40 mg, 60 mg, 80 mg) and intramuscular injection (20 mg/mL after reconstitution)
- Mechanism: dopamine D2 and serotonin 5-HT2A receptor antagonist with additional activity at 5-HT1A/1D/2C receptors
- Administration: oral formulation requires administration with food (≥500 kcal) for optimal absorption; IM formulation provides rapid onset for acute agitation
- Half-life: approximately 7 hours (oral); steady state achieved within 1-3 days
- Metabolism: primarily hepatic via aldehyde oxidase and CYP3A4; no active metabolites
- Excretion: primarily fecal (≈66%) with minor renal elimination (≈20%)
Benefits
- Reduces positive symptoms of schizophrenia (hallucinations, delusions) and improves negative symptoms (social withdrawal, apathy)
- Stabilizes mood rapidly during acute manic/mixed episodes in bipolar I disorder, facilitating earlier discharge and functional recovery
- Lower risk of significant weight gain, hyperlipidemia, and glucose dysregulation compared to some other second-generation antipsychotics
- Flexible dosing and formulation options support individualized treatment plans across care settings
- Demonstrated efficacy in maintenance therapy, reducing relapse rates in both schizophrenia and bipolar disorder
- Generally favorable tolerability profile with lower incidence of sedation and anticholinergic effects than some alternatives
Common use
Geodon is FDA-approved for the treatment of schizophrenia in adults and for acute manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate. It is also used off-label in certain cases of treatment-resistant depression (as an augmenting agent), agitation in dementia (with caution), and borderline personality disorder. In clinical practice, it is often selected for patients who have experienced metabolic side effects (e.g., weight gain, dyslipidemia) on other antipsychotics, or who require a formulation with rapid onset for agitation management.
Dosage and direction
For schizophrenia:
- Initial dose: 20 mg twice daily with food
- Titration: may increase to 60 mg or 80 mg twice daily based on tolerability and response; maximum recommended dose 80 mg twice daily
- Maintenance: lowest effective dose should be used; periodic reassessment recommended
For acute bipolar manic/mixed episodes:
- Initial dose: 40 mg twice daily with food
- Titration: increase to 60 mg or 80 mg twice daily on day 2; effective dose range 40–80 mg twice daily
Intramuscular formulation (acute agitation in schizophrenia):
- Dose: 10 mg to 20 mg, may be repeated every 4 hours up to maximum 40 mg/day
- Switch to oral formulation as soon as clinically appropriate
Administration note: Must be taken with at least 500 kcal of food to achieve adequate bioavailability (approximately double absorption compared to fasting state).
Precautions
- QT prolongation: Geodon is associated with dose-related QT interval prolongation. Avoid use in patients with known QT prolongation, recent MI, or uncompensated heart failure. Pre-treatment ECG recommended in at-risk patients; periodic monitoring advised.
- Neuroleptic Malignant Syndrome (NMS): Monitor for hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability; discontinue immediately if suspected.
- Tardive Dyskinesia (TD): Risk may increase with duration of treatment and total cumulative dose. Use lowest effective dose; periodically reassess need for continued treatment.
- Metabolic changes: Monitor weight, blood glucose, and lipids at baseline and periodically during treatment, though risk is lower than with some other antipsychotics.
- Cerebrovascular adverse events: Increased incidence observed in elderly patients with dementia-related psychosis; not approved for this population.
- Hyperprolactinemia: May occur; monitor for clinical manifestations (e.g., galactorrhea, amenorrhea).
- Seizures: Use cautiously in patients with history of seizures or conditions that lower seizure threshold.
- Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic use.
Contraindications
- Known hypersensitivity to ziprasidone or any component of the formulation
- History of QT prolongation (including congenital long QT syndrome)
- Recent acute myocardial infarction
- Uncompensated heart failure
- Concomitant use with other drugs known to prolong QT interval (e.g., quinidine, dofetilide, sotalol, thioridazine, chlorpromazine, moxifloxacin, mefloquine)
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
Possible side effect
Common (≥5%):
- Somnolence (14%)
- Respiratory tract infection (8%)
- Extrapyramidal symptoms (8%)
- Dizziness (8%)
- Nausea (8%)
- Constipation (8%)
- Akathisia (8%)
- Abnormal vision (6%)
- Asthenia (6%)
- Rash (4%)
Less common but clinically significant:
- Orthostatic hypotension
- Tachycardia
- Weight gain (mean ≈2 kg in long-term studies)
- QTc prolongation (dose-dependent)
- Hyperprolactinemia
- Dyspepsia
- Dry mouth
- Tremor
- Anxiety
Rare but serious:
- Neuroleptic malignant syndrome
- Tardive dyskinesia
- Seizures
- Priapism
- Venous thromboembolism
- Allergic reactions (including anaphylaxis)
Drug interaction
- CYP3A4 inhibitors (e.g., ketoconazole): Contraindicated; may significantly increase ziprasidone exposure
- CYP3A4 inducers (e.g., carbamazepine): May decrease ziprasidone levels; consider dose adjustment
- QT-prolonging agents: Additive risk of arrhythmias; avoid concomitant use
- Antihypertensives: May potentiate orthostatic hypotension
- CNS depressants (e.g., benzodiazepines, alcohol): Additive sedative effects
- Levodopa and dopamine agonists: May antagonize effects
- Alpha1-adrenergic antagonists: Potential additive effects
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. Consistent administration with food is critical for maintaining stable pharmacokinetics.
Overdose
Symptoms: Sedation, tremor, hypotension, tachycardia, QTc prolongation. In large overdoses, delirium, coma, and extrapyramidal symptoms may occur. Management: No specific antidote exists. Provide supportive care including continuous cardiac monitoring (due to QT prolongation risk), management of hypotension (IV fluids, vasopressors if needed), and airway protection if CNS depression is significant. Activated charcoal may be considered if ingestion was recent. Avoid epinephrine and other drugs that prolong QT interval in management. Dialysis is not expected to be effective.
Storage
Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). Keep in original container, tightly closed, and protect from light and moisture. Do not freeze. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. The intramuscular formulation must be reconstituted immediately before use and any unused portion discarded.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Geodon is a prescription medication that should be used only under the supervision of a qualified healthcare provider. Individual response to therapy may vary. Patients should not initiate, discontinue, or change dosage without consulting their physician. Full prescribing information, including boxed warnings, should be reviewed before use. Only a healthcare professional can assess whether this medication is appropriate for a specific individual based on their medical history, current condition, and other factors.
Reviews
Clinical studies demonstrate that Geodon significantly improves PANSS scores in schizophrenia and YMRS scores in bipolar mania compared to placebo. In a 52-week maintenance study, ziprasidone demonstrated significantly longer time to relapse compared to placebo in schizophrenia. Many clinicians report particular value in patients who have experienced metabolic issues on other antipsychotics. Patient reviews often mention improved mental clarity and fewer metabolic concerns, though some report initial akathisia or nausea that often diminishes with time. The requirement to take with food is frequently noted as a minor inconvenience. Overall, it is considered an effective option with a distinct side effect profile within the atypical antipsychotic class.